Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines - PubMed (original) (raw)

Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines

Osama Abu-Hammad et al. Vaccines (Basel). 2021.

Abstract

Background Distribution of COVID-19 vaccines has been surrounded by suspicions and rumors making it necessary to provide the public with accurate reports from trustworthy experts such as healthcare professionals. Methods We distributed a questionnaire in Jordan among physicians, dentists and nurses who received a COVID-19 vaccine to explore the side effects (SE) they encountered after the first or the second dose of one of three vaccines namely: AstraZeneca Vaxzevria (AZ), Pfizer-BioNTeck (PB), and SinoPharm (SP) vaccines. Results A total of 409 professionals participated. Approximately 18% and 31% of participants reported no SE after the first dose and second dose, respectively. The remainder had mostly local side effects related to injection site (74%). Systemic side effects in the form of fatigue (52%), myalgia (44%), headache (42%), and fever (35%) prevailed mainly after the first dose. These were significantly associated with AZ vaccine, and age ≤ 45 years (p = 0.000 and 0.01, respectively). No serious SE were reported. Conclusions We can conclude that SE of COVID-19 vaccines distributed in Jordan are within the common range known so far for these vaccines. Further studies are needed to include larger sample size and longer follow-up period to monitor possible serious and long-term SE of the vaccines.

Keywords: AstraZeneca vaccine; COVID-19; Pfizer-Bionteck vaccine; SinoPharm; dentists; healthcare professionals; nurses; physicians; side effects.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Reported side effects of vaccines arranged according to their frequency. AZ: AstraZeneca Vaxezevira; PB: Pfizer BioNTech vaccine, SP: SinoPharm vaccine.

Similar articles

• Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study.
  Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, Abbas H, Rababah L, Rabadi M, Karasneh R, Aldeyab MA. Omeish H, et al. Hum Vaccin Immunother. 2022 Dec 31;18(1):1981086. doi: 10.1080/21645515.2021.1981086. Epub 2021 Oct 6. Hum Vaccin Immunother. 2022. PMID: 34614383 Free PMC article.
• Long-term adverse events of three COVID-19 vaccines as reported by vaccinated physicians and dentists, a study from Jordan and Saudi Arabia.
  Dar-Odeh N, Abu-Hammad O, Qasem F, Jambi S, Alhodhodi A, Othman A, Abu-Hammad A, Al-Shorman H, Ryalat S, Abu-Hammad S. Dar-Odeh N, et al. Hum Vaccin Immunother. 2022 Dec 31;18(1):2039017. doi: 10.1080/21645515.2022.2039017. Epub 2022 Mar 3. Hum Vaccin Immunother. 2022. PMID: 35240939 Free PMC article.
• Are some COVID-19 vaccines better than others regarding the short-term side effects?
  Al-Zidan R, Darweesh O, Salah M, Bebane P, Ahmed H, Abdulrazzaq G, Shanshal S, Alomari N. Al-Zidan R, et al. Ceska Slov Farm. 2023 Winter;72(1):45-54. Ceska Slov Farm. 2023. PMID: 36858979 English.
• The Side Effects and Adverse Clinical Cases Reported after COVID-19 Immunization.
  Rabail R, Ahmed W, Ilyas M, Rajoka MSR, Hassoun A, Khalid AR, Khan MR, Aadil RM. Rabail R, et al. Vaccines (Basel). 2022 Mar 22;10(4):488. doi: 10.3390/vaccines10040488. Vaccines (Basel). 2022. PMID: 35455237 Free PMC article. Review.
• COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
  Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. Meo SA, et al. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.

Cited by

• COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine.
  Abukhalil AD, Abushehadeh RR, Shatat SS, Al-Shami N, Naseef HA, Ladadweh H, Madia R. Abukhalil AD, et al. Int J Gen Med. 2024 Jul 30;17:3349-3360. doi: 10.2147/IJGM.S466838. eCollection 2024. Int J Gen Med. 2024. PMID: 39100722 Free PMC article.
• Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
  Jaber HM, Ebdah S, Al Haj Mahmoud SA, Abu-Qatouseh L, Jaber YH. Jaber HM, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2333104. doi: 10.1080/21645515.2024.2333104. Epub 2024 Apr 7. Hum Vaccin Immunother. 2024. PMID: 38584118 Free PMC article.
• Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population.
  Moradi Hasan-Abad A, Arbabi M, Gilasi H, Motedayyen H. Moradi Hasan-Abad A, et al. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241239202. doi: 10.1177/03946320241239202. Int J Immunopathol Pharmacol. 2024. PMID: 38494849 Free PMC article.
• Short-term side effects of COVID-19 vaccines among healthcare workers: a multicenter study in Iran.
  Mirnia K, Haji Esmaeil Memar E, Kamran N, Yeganedoost S, Nickhah Klashami Z, Mamishi S, Mahmoudi S. Mirnia K, et al. Sci Rep. 2024 Feb 19;14(1):4086. doi: 10.1038/s41598-024-54450-w. Sci Rep. 2024. PMID: 38374372 Free PMC article.
• Assessment of adverse events among healthcare workers following the Janssen COVID-19 vaccine in Tigray, Ethiopia.
  Abera BT, Teka H, Berhe E, Gebru MA, Zenebe D, Abraha HE, Hailu A. Abera BT, et al. Sci Rep. 2024 Feb 8;14(1):3255. doi: 10.1038/s41598-024-53561-8. Sci Rep. 2024. PMID: 38332047 Free PMC article.

References

1. 1. Khan Y.H., Mallhi T.H., Alotaibi N.H., Alzarea A.I., Alanazi A.S., Tanveer N., Hashmi F.K. Threat of COVID-19 Vaccine Hesitancy in Pakistan: The Need for Measures to Neutralize Misleading Narratives. Am. J. Trop. Med. Hyg. 2020;103:603–604. doi: 10.4269/ajtmh.20-0654. - DOI - PMC - PubMed
2. 1. Abu-Hammad O., Alnazzawi A., Borzangy S.S., Abu-Hammad A., Fayad M., Saadaledin S., Abu-Hammad S., Dar-Odeh N. Factors Influencing Global Variations in COVID-19 Cases and Fatalities; A Review. Healthcare. 2020;8:216. doi: 10.3390/healthcare8030216. - DOI - PMC - PubMed
3. 1. WM. [(accessed on 24 March 2021)]; Available online: https://www.worldometers.info/coronavirus/#countries.
4. 1. Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. doi: 10.1016/S0140-6736(20)32466-1. - DOI - PMC - PubMed
5. 1. CDC. [(accessed on 17 April 2021)]; Available online: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html.

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • MDPI
  • PubMed Central